Dendritic cells (DCs) are antigen-presenting cells that normally play a critical role in stimulating T-cell-dependent immune responses. However, tolerogenic DCs (CD11c + MHC-II low C-D80 low/2 CD86 low/2 ) induce immune tolerance by stimulating regulatory T cells (Tregs: CD4 + CD25 + Foxp3 + ). Although tolerogenic DCs are used to treat autoimmune diseases and to prevent transplantation rejection, the mechanisms by which they regulate alloimmunity are poorly understood. Here, we review our previous studies aiming to elucidate the mechanisms involved in immune rejection of corneal allografts using a corneal transplant model. We found that donor-derived tolerogenic DCs significantly prolonged corneal allograft survival by suppressing indirect allosensitization. We also reported the precise distribution of intraepithelial corneal DCs, termed Langerhans cells (LCs: CD11c + Langerin + MHC-II +/2 ) in the cornea, which we maintain play a critical role in regulating corneal immunity. By confocal microscopy, we constructed 3-dimensional images of corneal LCs, which demonstrated that their cell bodies are present in the basal cell layer of the corneal epithelium. Furthermore, LC dendrites extend toward the ocular surface, but do not connect to epithelial tight junctions, indicating that they cannot directly interact with ocular surface antigens. We confirm the potential of DC therapy for corneal graft rejection and report the function of intraepithelial DCs (LCs) in the normal cornea.
D endritic cells (DCs) and related intraepithelial DCs, also known as Langerhans cells (LCs), are professional antigen-presenting cells (APCs) that stimulate T-cell-dependent immune responses. Based on basic research on these cells, DCs are currently being investigated in the clinic for treatment of several diseases. 1 This article provides novel information on DC therapy for corneal transplantation survival and the distribution of LCs in the normal cornea.
FUNCTIONS OF MATURE, IMMATURE, AND TOLEROGENIC DCs
DCs are APCs that stimulate T-cell-dependent immune responses upon antigen presentation. 2 Tissue DCs are considered immature (CD11c + MHC-II low CD80/86 low ) because they do not have the capacity to sensitize T cells and induce immune tolerance by inducing apoptosis or anergy of T cells, or by stimulating regulatory T cells (Tregs, CD4 + CD25 + forkhead box [Fox] p3 + ) ( Fig. 1 ). 3, 4 It is thought that DCs act as sentinels in tissues by capturing and processing antigens. After charging their surface MHC class II molecules with immunogenic peptides, they develop into mature DCs (mDCs, CD11c + MHC-II high CD80/86 high ), traffic to the lymphoid organs, and sensitize antigen-specific T cells ( Fig. 1 ). 4 Immature DCs (iDCs), which maintain their immunosuppressive functions even during inflammation, were recently termed tolerogenic DCs (CD11c + MHC-II low CD80 low/2 CD86 low/2 ) ( Fig.  1) . 5 In an effort to generate tolerogenic DCs, in vitropropagated DCs have been manipulated by exposure to various antiinflammatory and immunosuppressive agents. 6 
USE OF TOLEROGENIC DCs FOR TRANSPLANTATION
Tolerogenic DCs are effective for preventing transplantation rejection in various animal models of organ transplantation. 5, 7, 8 Rapamycin-conditioned DCs administered to host mice prolonged heart 9,10 and skin graft survival. 11 Administration of DCs treated with the vitamin D 3 metabolite, 1a,25dihydroxyvitamin D 3 (1a,25(OH) 2 D 3 ), promoted tolerance to mouse pancreatic islet allografts. 12 Administering donor-derived DCs exposed to agonistic paired immunoglobulin-like receptor B monoclonal antibodies prolonged skin allograft survival in mice. 13 Administration of bone marrow-derived DCs generated in vitro using granulocyte-macrophage colony-stimulating factor, interleukin-10, and transforming growth factor-b, followed by pulsing with lipopolysaccharide, prevented lethal graft-versus-host disease after allogeneic bone marrow transplantation in sublethal-irradiated mice. 14 These tolerogenic DCs are termed DCregs. DCregs also promote survival following murine heart transplantation. 15 
USE OF TOLEROGENIC DCs FOR CORNEAL TRANSPLANTATION
We previously reported that administration of donorderived tolerogenic DCs suppressed corneal transplant rejection. 16 We performed a DCreg (CD11c + MHC-II low CD80 low /-CD86 low / -CD200R3 + ) adoptive transfer experiment in which DCregs isolated from C57BL/6 mice were transferred intravenously to corneal allograft recipients (BALB/c) before surgery. mDCs (CD11c + MHC-II high CD80 high CD86 high CD200R3 2 ) and iDCs (CD11c + MHC-II low CD80 low CD86 low CD200R3 2 ) were transferred as control cells. The adoptive transfer of 1 · 10 6 DCregs significantly increased allograft survival compared with iDC-and mDC-treated recipient mice, as well as untreated recipient mice ( Fig. 2 ). In addition to our study, another group also reported efficacy of tolerogenic DCs for corneal transplantation. Glucocorticoid-treated donor bone marrow-derived DCs prolonged corneal allograft survival. 17 Khan et al 18 established novel tolerogenic DCs that inhibited expression of CD80/86 using a fusion protein, CTLA4-KDEL. Administration of CTLA4-K-DEL-expressing DCs resulted in long-term survival of corneal allografts. 18 
MECHANISM UNDERLYING GRAFT REJECTION SUPPRESSION BY TOLEROGENIC DCs

Impairment of T-Cell Immune Reactions
The mechanisms by which tolerogenic DCs suppress allogeneic response have been studied. Rapamycin-treated DCs are poor producers of the cytokines interleukin-12p70 and tumor necrosis factor and impair T-cell immune reactions. 9 These rapamycin-treated DCs can stimulate naturally occurring Tregs, in addition to their ability to inhibit expansion of CD4 + effector T-cell populations. 19 Administration of donor-derived DCs treated with 1a,25(OH) 2 D 3 promoted survival of mouse pancreatic islet allografts by inducing CD4 + CD25 + Foxp3 + Tregs. 12 DCregs also promote CD4 + CD25 + Foxp3 + Tregs and suppress antigen-specific autologous T-cell activation. 15, 20 We also reported that administration of donor-derived DCregs suppressed Th1 responses and expanded the population of CD4 + CD25 + Foxp3 + Tregs in a mouse corneal transplantation model. 16 The percentage of CD4 + IFN-g + cells in cervical lymph nodes after 3 weeks of corneal transplantation was approximately 1.0% in iDC-and mDC-treated recipient mice, as well as untreated recipient mice. Numbers of CD4 + IFN-g + cells in DCreg-treated recipient mice (0.6%) were decreased compared with iDC-and mDC-treated recipients, as well as untreated recipients. To determine whether DCregs generated Tregs in vivo, we assayed for expression of mRNA for Foxp3 in draining lymph nodes after corneal transplantation of DCreg-treated, mDC-treated, and untreated recipients. Effect of iDCs, mDCs, and tolerogenic DCs on T-cell immunity. Steady-state iDCs remain quiescent after capturing and processing exogenous antigen. These quiescent iDCs express low levels of costimulatory molecules, and therefore cause deficient activation of naive T cells, and induce T-cell apoptosis or anergy and probably generation and/or expansion of regulatory T cells (Tregs). In contrast, after exposure to danger signals and/or activation and maturation stimuli, iDCs increase surface expression of MHC and costimulatory molecules, which enhance their ability to stimulate naive or memory T cells. Tolerogenic DCs present antigen to antigen-specific T cells but fail to deliver adequate costimulatory signals for effector T-cell activation and proliferation. This may manifest as T-cell death, T-cell anergy, or Treg expansion or generation. FIGURE 2. Donor-derived regulatory dendritic cells (DCregs) prolong corneal graft survival. iDCs, mDCs, and DCregs were generated from C57BL/6 mouse bone marrow cells as described previously by Sato et al. 14 Donor-derived mDC (1 · 10 6 )-, iDC (1 · 10 6 )-, or DCreg (0.2 · 10 6 , 1 · 10 6 )-infused BALB/c mice or untreated mice were transplanted with C57BL/6 corneas, and graft survival was followed microscopically for 8 weeks (n = 6 per group). Kaplan-Meier survival curves indicate that infusion of 1 · 10 6 donor-derived DCregs prolonged graft survival (*P = 0.043). Reproduced and modified from Hattori et al 16 with permission from the Journal of Leukocyte Biology.
Expression of Foxp3 in the DCreg-treated group was higher than that in the untreated and mDC-treated groups (Fig. 3B ).
Suppression of Direct and Indirect Pathways of Allorecognition
Graft rejection is caused by 2 different types of host allosensitization: the direct and the indirect pathways. 21 The direct pathway involves T cells that respond directly to foreign MHC molecules expressed by donor-derived APCs (Fig. 4 ). In the indirect pathway, recipient APCs present donor-derived allopeptides in the context of self-MHC (Fig.  4) . The direct pathway has classically been considered to be the most powerful mechanism involved in acute graft rejection. The indirect pathway is predominant at later time points after transplantation and is the main mechanism underlying allorecognition that triggers chronic rejection. Tolerogenic DCs have been used to interfere with the direct and indirect pathways of allorecognition with the aim of prolonging allograft survival. 7 We reported that donor-derived DCregs suppressed indirect pathway-type allosensitization in mouse corneal transplant recipients. 16 We measured posttransplantation alloreactive T-cell frequencies of untreated versus DCreg-infused recipients using an ELISPOT assay system (IFN-g). We found that untreated recipients had increased direct and indirect pathway-type allosensitization compared with naive mice (Figs. 5C, D) . However, the magnitude of the increase was much higher in the indirect pathway (28-fold increase) than the direct pathway (1.4-fold increase), suggesting that corneal graft rejection is indirect pathway dominant. This result was in accordance with previous studies. [22] [23] [24] Strikingly, DCreg-infused recipients showed decreased direct (P = 0.007) and indirect (P = 0.0007) pathway-type allosensitization relative to untreated recipients; the magnitude of reduction was significantly higher in the indirect pathway (30-fold reduction) than in the direct pathway (1.5-fold reduction) (Figs. 5C, D). Therefore, taken together, these data suggest that donor-derived DCregs suppress both the direct and the indirect pathways of allosensitization in corneal transplant recipients, but relative suppression is greatest for indirect sensitization.
Interestingly, Divito et al 25 showed that injected donor-derived DCregs were processed by the recipient's quiescent conventional DCs in a mouse model of heart transplantation. These host DCs in turn promoted deletion of donor-specific effector T cells with consequent increases in the relative number of donor-specific CD4 + CD25 + Foxp3 + Tregs. 25 Processing of injected donor-derived DCregs by host DCs can explain why donor-derived DCregs suppress rejection of corneal allografts that mostly occurs through the indirect pathway of allorecognition. Thus, the tolerogenic status of host conventional DCs that process injected tolerogenic DCs seems to be key for the success of tolerogenic DC therapies. 7 
FIGURE 3. Infusion of donor-derived regulatory dendritic cells (DCregs) impairs T-cell differentiation
in corneal graft recipients. C57BL/6 corneas were transplanted into BALB/c mice. For infusion of DCs into recipients, 1 · 10 6 iDCs, mDCs, or DCregs generated from C57BL/6 mouse bone marrow cells were injected intravenously through the lateral tail vein 7 days before transplantation. A, T cells were isolated from draining lymph nodes 3 weeks posttransplantation (n = 3 per group). Isolated T cells obtained from DCreg/mDC-infused recipients or untreated recipients were stimulated with PMA/ionomycin and IFN-g + (CD4 + and CD4 2 fractions) and were subsequently measured by flow cytometry. B, mRNA was isolated from draining lymph nodes 3 weeks posttransplantation (n = 3 per group). 
LCs IN THE NORMAL CORNEA
The cornea was thought to be an immune privileged tissue 26 because of the absence of APCs in the normal cornea. 27 However, subsequent studies revealed that a significant number of highly immature MHC-APCs reside in the normal cornea. 28 Furthermore, significant numbers of DCs exist in the corneal epithelium (as LCs) and anterior stroma (as stromal DCs), and the posterior stroma contains high numbers of macrophages. 28 Langerin, a c-type lectin expressed by specific DCs such as LCs, recognizes pathogenic mycobacteria. 29 We previously reported the presence of CD11c + Langerin + LCs in the normal corneal epithelium. 30 Most Langerin + LCs also express MHC-II, but some are MHC-II negative.
Functions of Corneal LCs
The importance of LCs in the induction of immunoreactions against corneal microbial infection has been reported. Administration of LCs to the central cornea before Pseudomonas infection in BALB/c mice led to severe microbial keratitis. 31 The presentation of herpes simplex virus antigen on LCs favored activation and accumulation of CD4 + T lymphocytes in herpes simplex virus-1-infected mouse corneas. 32 Thus, LCs in the cornea are associated with induction and amplification of immunoinflammatory responses in microbial and bacterial keratitis. However, how corneal LCs recognize these microbes is still unclear.
The mechanisms by which skin LCs uptake skin surface antigen have been determined using 3-dimensional (3D) images of skin LCs. Beneath the stratum corneum (SC), tight junctions (TJs) seal the paracellular spaces between keratinocytes at the stratum granulosum layer of the epidermis in mice. 33 Skin LCs form a network within the epidermis underneath TJs. 34 Stratum corneum damage in mice activates LCs, whose dendrites elongate, penetrate into the TJ barrier, take up antigens from the extra-TJ environment, 34 and trigger protective T helper 2 responses. 35 Based on these findings, we wanted to understand how corneal LCs uptake ocular surface antigens. We tried to establish 3D images of corneal LCs using the same methods used for skin LCs. 34 We facilitated 3D visualization of whole-mount corneas by confocal microscopy. We also studied the physiological interaction between the physical corneal barrier and corneal LCs. Corneas were harvested from naive C57BL/6 mice and fixed with methanol. Anti-ZO-1 antibody (Abcam, Cambridge, MA) was used to stain corneal epithelial TJs, and anti-MHC-II antibody (BioLegend, San Diego, CA) was used to stain corneal LCs. Images of stained corneas were captured by confocal microscopy (LMS700; Carl Zeiss, Thornwood, NY) and analyzed using an image analyzer (ZEN; Carl Zeiss). Three-dimensional reconstruction images of ZO-1 staining demonstrated that TJs sealed the paracellular pathway of double or triple layers of superficial cells (Fig. 6 ). We evaluated the positioning of LC dendrites in relation to TJs. Three-dimensional reconstruction images showed that most LC bodies existed in the basal cell layer, and an upward projection of LC dendrites toward the corneal surface, which stopped at the wing cell layer with obvious spaces between dendrite tips and TJs, was observed ( Fig. 6) . These results indicate that corneal LCs in the normal cornea (without a compromised epithelial layer) do not uptake foreign materials that have not penetrated the ocular surface epithelium.
SUMMARY, CONCLUSION, AND FUTURE DIRECTIONS
Previous studies, including our own, have demonstrated the therapeutic effect of donor-derived tolerogenic DCs on FIGURE 5 . Donor-derived regulatory dendritic cells (DCregs) suppress the indirect pathway in corneal transplant recipients. C57BL/6 corneas were transplanted to BALB/c mice. For infusion of DCregs into recipients, 1 · 10 6 DCregs generated from C57BL/6 mouse bone marrow cells were injected intravenously through the lateral tail vein 7 days before transplantation. T cells were isolated from draining lymph nodes of untreated and DCreg-infused recipients (n = 4 per group) 3 weeks posttransplantation, and were measured by IFN-g ELISPOT assay. Isolated T cells were cocultured with allogeneic APCs to measure the direct pathway or cocultured with syngeneic APCs in the presence of alloantigen to measure the indirect pathway. A and B, Triplicate enzyme-linked immunospot wells for IFN-g production responder T cells after 48 hours of culture from each group [direct pathway: (A); indirect pathway: (B)]. C, Donor-derived DCregs reduced the frequency of direct pathway-type alloreactivity compared with untreated recipients. *P = 0.007. D, Donor-derived DCregs also reduced the frequency of indirect pathway-type alloreactivity relative to untreated recipients. **P = 0.0007. Moreover, the reduction (30.2-fold) was much higher than in the direct pathway (1.5-fold). Data are representative of 2 experiments. Reproduced and modified from Hattori et al 16 with permission from the Journal of Leukocyte Biology. corneal transplant survival. Moreover, we showed that donorderived DCregs suppressed both the direct and indirect pathways of allosensitization, an ideal strategy for maximizing long-term transplant survival through allotolerance.
We also determined the localization of LC dendrites in relation to TJs of the epithelium in the normal cornea. Three-dimensional reconstruction images demonstrated an upward projection of LC dendrites toward the ocular surface, which stopped at the wing cell layer without interacting with TJs, indicating that normal corneal LCs do not uptake ocular surface antigens when the epithelium is intact. It is still unclear how corneal LCs uptake ocular surface antigens in immunopathogenic conditions. Our experimental methods using 3D reconstruction images of corneal LCs might help expand our understanding of how corneal LCs uptake ocular surface antigens in immunopathogenic conditions such as infectious keratitis or allergic keratoconjunctivitis.
